Made Scientific has entered a long-term agreement with Orca Bio to provide commercial manufacturing capacity for TREGZI at its Princeton, New Jersey, site. TREGZI is Orca Bio’s FDA-approved cell therapy for use in allogeneic transplants in adults with hematologic malignancies.
The Princeton operation will serve as an East Coast production site alongside Orca Bio’s main commercial manufacturing facility in Sacramento, California. The companies say having production on both coasts could shorten delivery times for some East Coast patients. The arrangement will also allow Orca Bio to manufacture products using cells from European donors and provide additional access to domestic and international donors.
Made Scientific, a U.S.-based contract development and manufacturing organization specializing in cell therapies, plans to add a 45,000-square-foot facility next to its existing Princeton site. The two sites will form a manufacturing campus, with the new facility housing additional commercial-scale manufacturing suites, quality control laboratories, warehousing and cryogenic storage.
Made Scientific is working toward FDA licensure of its Princeton facilities to support commercial supply for Orca Bio. Orca Bio Co-founder and President Jeroen Bekaert said Made Scientific would support both clinical and commercial manufacturing. Orca Bio, which will retain Sacramento as its main commercial production site, develops cell therapies for blood cancers and autoimmune diseases.